The LDHA inhibitor Oxamate, acting via direct targeting of LDHA activity by suppressing a conversion of pyruvate to lactate, was reported to suppress cell growth in cetuximab (EGFR inhibitor) resistance HNSCC cells in vitro [56] or to inhibit tumor growth in vivo [57]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.